Centre Hospitalier Universitaire d'Angers

MONTREAL, May 27, 2021 (GLOBE NEWSWIRE) -- Brain Canada and the Barbara Turnbull Foundation for Spinal Cord Research are pleased to announce that Dr. Steve Lacroix has been selected by an international panel to receive the 2020 Turnbull-Tator Award in Spinal Cord Injury and Concussion Research. Dr. Lacroix is being recognized for his publication “Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury,” published in Nature Communications in 2019. Since 2001, in honour of Barbara Turnbull, Brain Canada and the Barbara Turnbull Foundation have been partnering to support the need for exceptional research in the area of spinal cord and/or brain injury to improve the lives of those affected. Co-sponsored by the foundations, the Turnbull-Tator Award recognizes an outstanding publication by a Canadian researcher in the field. Selected based on the innovation and impact of the research and its findings, the recipient of the Award is provided with a $50,000 grant to continue their research and contribute towards advancing the research area. “Barbara was a dedicated advocate for raising awareness and drawing public attention to the importance of recognizing and supporting excellence in Canadian-based research in areas relevant to spinal cord injury remediation and concussion assessment and treatment,” says Gary Goldberg, a director of the Barbara Turnbull Foundation for Spinal Cord Research. “It is a privilege to carry out her legacy through the Barbara Turnbull Foundation as she continues to be an inspiration for those working to make a difference in this field.” Nominated by Dr. Serge Rivest, Dr. Lacroix is a leading Canadian neuroscientist with more than 15 years of experience in spinal cord research. His work focuses on protecting neurons following injury and promoting spinal cord regeneration and repair. “I am humbled and grateful to accept this award in honour of pioneers who have dedicated their lives to research in the field of spinal cord injury,” says Dr. Lacroix, Professor in the Department of Molecular Medicine, Faculty of Medicine at Université Laval and Director of the Neurosciences Axis at the CHU de Quebec–Université Laval Research Center. “Collaboration has been a huge factor in this achievement, as I would not have been able to publish on my own. I consider myself lucky to have worked with brilliant Canadian colleagues Dr. Molly Shoichet at the University of Toronto, Dr. Marie-Ève Tremblay now at the University of Victoria, and a team of great students and research assistants who all played important roles.” In the award-winning publication, Dr. Lacroix and his team use animal models to better understand the role of microglia – a type of immune cell found in the brain and spinal cord. They outline its effects in preventing neuronal death after a spinal cord injury and containing the spread of injury, thanks to what they have coined as the microglial scar. In addition, this paper has shown that a boost in the protective function of microglia could lead to improved recovery following injury. “Our sincere congratulations to Dr. Lacroix and his team,” says Dr. Viviane Poupon, Brain Canada President and CEO. “This publication is transformative for the research community and is the kind of high-quality and rigorous research that will change how spinal cord injury is studied while accelerating discoveries for treatments and recovery.” “The research that Dr. Lacroix and his team are conducting bring us all one step closer to achieving Barbara’s dream of improving the lives of people affected by life-altering injuries,” says Dr. Charles Tator, Professor of Neurosurgery at the University of Toronto and Scientist at the Krembil Brain Institute, University Health Network in Toronto. “I feel very privileged to have known Barbara and witnessed her infectious positivity and advocacy. She believed that people’s lives could be made better by science, and this is the essence of the award in our names.” It is currently estimated that there are 85,000 people with spinal cord injury in Canada, with 4,500 new cases each year. These numbers are expected to rise over the next two decades due to Canada’s aging population. “This funding from Brain Canada and the Barbara Turnbull Foundation is really essential for us to remain competitive internationally and develop innovative ways to understand something as complex as spinal cord repair,” said Dr. Lacroix. “My goal is to deliver the best research possible and hopefully inspire the next generation of Canadian scientists so they can shape the future of spinal cord injury research.” This project has been made possible with the financial support of Health Canada, through the Canada Brain Research Fund, an innovative partnership between the Government of Canada (through Health Canada) and Brain Canada, and the Barbara Turnbull Foundation for Spinal Cord Research. About the Barbara Turnbull Foundation for Spinal Cord Research The initial purpose of the Foundation was to encourage the public to recognize and financially support internationally esteemed research being done in Canada in the field of neuroscience, particularly as it relates to the remediation of spinal cord injuries. More recently, the Foundation has expanded its area of interest to include both spinal cord and brain injuries, including concussions. Great advances have been made in neuroscience, and the driving force that encouraged Barbara Turnbull to write her autobiography Looking in the Mirror was the realization that these advances may make the goal of regaining function in the damaged nervous system attainable. Through continued research, there is the possibility of new discoveries which may result in repair or regeneration of the spinal cord and brain after injury. Successful remediation will improve the quality of life of those who have been affected by neurotrauma, as well as reduce the ongoing costs of providing associated care and support. Based on a synergistic approach that recognizes excellence in collaborative research in Canada in the field of neuroscience, the mission of the Foundation is to enhance public awareness of the need to financially support this vision, to develop strategic cooperative initiatives with other institutions and foundations with similar interest, such as Brain Canada, and to fund the highest quality research in spinal cord and brain injury being conducted in Canada. About Brain Canada Brain Canada is a national non-profit organization that enables and supports excellent, innovative, paradigm-changing brain research in Canada. It plays a unique and invaluable role as the national convener of the brain research community. Brain Canada understands that better insight into how the brain works contributes to the prevention, diagnosis, treatment and cure of disorders of the brain, thereby improving the health outcomes and quality of life of all Canadians. To learn more, please visit braincanada.ca. About the Turnbull-Tator Award In 2001, the Barbara Turnbull Foundation, Brain Canada, and CIHR’s Institute of Neurosciences, Mental Health and Addiction established a partnership to recognize and support excellent brain research in the area of spinal cord injury. In 2019, the Barbara Turnbull Foundation for Spinal Cord Research and Brain Canada expanded the scope of the Award to include traumatic brain injury and concussion research, and to reposition the award to recognize a recent publication that significantly impacts those fields. Accordingly, the name of the Award was changed to reflect the close relationship, sense of common purpose, and aligned missions of both Barbara Turnbull and her neurosurgeon, Dr. Charles Tator, to promote awareness of the impact of spinal cord injury and its prevention, research into its treatment, and a better understanding of the nature, diagnosis, and treatment of concussion and traumatic brain injury. To learn more about the history of the Turnbull-Tator Award, click here. Applications for the Turnbull-Tator Award were reviewed by members of an international peer review panel chaired by Dr. Charles Tator and composed of experts with experience in the relevant field(s) of spinal cord and/or brain injury research. Based on the reviewers' scores and panel discussion, the review panel recommended to the Barbara Turnbull Foundation and Brain Canada the top-ranked publication to receive the Award. For more information : Melissa Arauz Brain Canada melissa.arauz@braincanada.ca 514-377-6461 A photo accompanying this announcement is available at Recipient of the 2020 Turnbull-Tator Award in Spinal Cord Injury and Concussion Research Dr. Steve Lacroix, Professor in the Department of Molecular Medicine, Faculty of Medicine at Université Laval and Director of the Neurosciences Axis at the CHU de Quebec–Université Laval Research Center.

Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus® Commercial Launch Plans Advance ANN ARBOR, MI / ACCESSWIRE / January 13, 2021 / ENDRA Life Sciences (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued United States Patent 10888898 (the '898 patent) entitled "Shielded Ultrasound Transducer and Imaging System Employing the Same" from the United States Patent and Trademark Office. This is the 13th U.S. patent issued to ENDRA for its TAEUS® technology. "ENDRA's goal is to develop applications for our proprietary TAEUS® technology in areas of high unmet clinical need and for which there are no practical existing tools. The recently issued ‘898 patent provides more robust intellectual property (IP) protection for our TAEUS® platform in the key U.S. market where an estimated 30% of its 1.4 billion citizens are affected by Non-Alcoholic Fatty Liver Disease (NAFLD)," said Francois Michelon, ENDRA's chief executive officer. The '898 patent covers a transducer and system shielding and grounding configuration that mitigates the acoustic noise that a radiofrequency emitter generates in a thermoacoustic system. "Receipt of the '898 patent is a key step forward in the development of thermoacoustic imaging systems for a variety of clinical applications," added Mr. Michelon. "Our IP portfolio - which currently stands at 78 assets including patents in preparation, issued and licensed - continues to grow, providing valuable protection for our TAEUS® technology." ENDRA's commercial launch plans for TAEUS® include establishing clinical research partnerships worldwide, with an initial focus on Europe. To date the company has established five research partnerships including two in Europe, two in the U.S. and one in Canada. Most recently TAEUS® systems were installed at Centre Hospitalier Universitaire d'Angers in France, Rocky Vista University College of Osteopathic Medicine in Utah and the University of Pittsburgh Medical Center, where patients are being enrolled in clinical studies to assess NAFLD. In December 2020 ENDRA renewed its collaboration agreement with the GE Healthcare unit of General Electric Company, extending the agreement's term by two years to December 16, 2022. GE Healthcare is the global leader in clinical ultrasound and has been ENDRA's partner since 2016. TAEUS® is currently cleared for sale in countries that recognize the CE mark, including those in the European Union, and a 510(k) application has been submitted to the U.S. Food and Drug Administration. About NAFLD NAFLD is a condition closely associated with obesity, diabetes, hepatitis C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S. healthcare system over $100 billion annually. NAFLD is often asymptomatic and if left untreated, can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical, and include expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy. About ENDRA Life Sciences Inc. ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit . Forward-Looking Statements All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as the expectations regarding commercializing the TAEUS® device, establishing evaluation reference sites and initial sales in Europe, receipt of U.S. Food and Drug Administration regulatory approval and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology and the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this news release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law. Company Contact: David Wells Chief Financial Officer (734) 997-0464 investors@endrainc.com Investor Relations Contact: Kim Sutton Golodetz LHA Investor Relations (212) 838-3777 kgolodetz@lhai.com SOURCE: ENDRA Life Sciences Inc. View source version on accesswire.com: